Firefly Neuroscience (AIFF) said Tuesday its BNA technology platform is able to assess a patient's biological brain age using cognitive data, potentially leading to a "scalable" approach to early screening for Alzheimer's patients.
The US Food and Drug Administration-approved platform used resting electroencephalography, or EEG, and cognitive EEG to assess the biological age of a person's brain, the company said.
Chief Technology Officer Gil Issachar said the technology "is capable of finding a significant disparity between brain age and chronological age, which could serve as a valuable risk factor for dementia."
Shares of the company soared more than 111% in Tuesday's premarket activity.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。